Arvinas Holding Company recently held its earnings call, revealing a balanced sentiment among stakeholders. The company showcased strong clinical progress and significant collaborations, notably with ...

Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant – – ...

Guggenheim analyst Michael Schmidt maintained a Buy rating on Arvinas Holding Company yesterday and set a price target of $15.00. The company’s shares opened today at $6.61. Ele ...

Submitted New Drug Application for vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced or metastatic breast cancer – ...

Shares of Arvinas Inc. (ARVN) fell 4% on Thursday as Wall Street sounded contradicting opinions on the future of its ...

The smaller market now envisioned for vepdegestrant has changed both companies’ stance on their original deal, leading to ...

Q2 2025 Earnings Call Transcript August 6, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.83836, ...

Arvinas believes the differentiated pharmacology of ARV-471, including its iterative degradation activity, has the potential to translate into meaningful clinical benefit for patients.

Arvinas-stock News for Arvinas Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in ...

Arvinas' PROTAC approach has several advantages over conventional drugs, including the potential to target "undruggable" proteins, achieve tissue-specific targeting, and cross the blood-brain barrier.

The outperformance of Arvinas can be attributed to positive findings from a phase 1 study of its treatment for breast and prostate cancer. ARVN stock is also up 6x from levels of $13 seen in early ...

The stock price of Arvinas (NASDAQ: ARVN), a biopharmaceuticals company focused on oncology treatments based on targeted protein degradation, has fallen 24% in a month, while it’s down a ...